CD47 and neoplasm: We successfully demonstrated that the time-programmed sequential delivery of sorafenib and aCD47 could reeducate TAMs, reverse immunosuppressive TME, and enhance the CD47-blockade efficacy to inhibit the tumor recurrence, when applied to the surgical beds of mice with resected 4T1 tumors.